STING1 and neoplasm: These innovations enable precise regulation over the release and activation of multiple therapeutic agents in a spatiotemporally controlled manner, as demonstrated by recent work reported by Shuai et al.[73b] The authors developed a core‐shell nanoparticle with hierarchical tumor‐targeting capabilities to co‐deliver PD‐L1 antibodies (aPD‐L1) and the STING agonist interferon stimulatory DNA (ISD) (Figure 7).